Work

Patients with persistent atrial fibrillation and metabolic comorbidities have an altered inflammatory state of atrial epicardial adipose tissue, which is linked to CT-attenuation

Year: 2025

Type: article

Abstract: BACKGROUND: Epicardial adipose tissue (EAT) is linked to both Atrial fibrillation (AF) and metabolic syndrome (MetS). Whether EAT inflammation relates to AF type, recurrence after ablation, or MetS, is incompletely known, likewise if it can be measured by CT angiography. AIM: To establish the link between (1) atrial EAT inflammatory composition and AF type, AF recurrence, and metabolic comorbidities. (2) EAT inflammation and EAT-volume or density. METHODS: Patients undergoing thoracoscopic ablation for advanced AF (that is, usually persistent, with enlarged left atria and previous failed ablations) with a cardiac CT-scan before and 6 months after surgery were enrolled. CT-EAT atrial volume and attenuation (density), were used for analyses. Patients' left atrial appendages (LAA + EAT) were excised during ablation and stained for adipocytes and different inflammatory cells. RESULTS: , (p = 0.003), and less anti-inflammatory CD163 + macrophages: 126[134] versus 224[179], (p = 0.03). The AUC curve for differentiating persistent from paroxysmal AF through neutrophil-count was 0.75 (p value < 0.001, CI 0.63-0.87). EAT neutrophil-count related to CT-EAT-attenuation (multivariable analysis: expB 1.01, CI 1.00-1.02, (p = 0.04)). CT-EAT-attenuation distinguished persistent from paroxysmal AF: - 73.0 ± 4.6 versus - 75.3 ± 5.3HU, (p = 0.03). Patients with versus without recurrence had similar inflammatory cell counts, but larger adipocytes, multivariable analysis: ExpB 1.002, CI 1.00-1.003, (p = 0.02). Hypertensive and diabetic patients also had an increased adipocyte size. CONCLUSION: Patients with persistent versus paroxysmal AF exhibited increased EAT neutrophils, which is reflected by CT-EAT-attenuation. Those with AF recurrence, hypertension and diabetes had adipocyte hypertrophy which may imply a common mechanism underlying these conditions.

Source: Cardiovascular Diabetology

DOI: 10.1186/s12933-025-02985-1